2 vials Save $50

Retatrutide 10mg

Lyophilized research peptide

$137.49

BPC-157 10mg

15-residue peptide

$112.49

Research bundle · 2 vials

Retatrutide 10mg + BPC-157 10mg Research Bundle

USA Made, ≥99% Purity Per Compound

Separate retail vials: Retatrutide 10mg; BPC-157 10mg
USA manufactured in a Certified GMP California and Arizona laboratory.
≥99% purity target per compound with third-party HPLC, mass spectrometry, and batch-specific COAs

Combined retail value$249.98

Bundle saving−$50.00

$199.98 $249.98 Save $50

Each vial ships in its original retail format with its own batch COA

Dispatched from a US warehouse within 48 hours, tracked

Store at -20°C (Freeze) or 2–8°C (Refrigerated) protected from light

Disclaimer

For research purposes only. Not intended for human consumption, medical use, diagnosis, treatment, or prevention of disease.

Per-compound specifications

2 vials

Nothing in this bundle is co-formulated. Each vial keeps its own identity, purity target, and certificate, and is specified separately below.

Vial 01

Retatrutide 10mg

Sequence

Tyr-Aib-Gln-Gly-Thr-Phe-Thr-Ser-Asp-Tyr-Ser-Ile-α-Me-Leu-Leu-Asp-Lys-Lys(AEEA-γGlu-C20 diacid)-Ala-Gln-Aib-Ala-Phe-Ile-Glu-Tyr-Leu-Leu-Glu-Gly-Gly-Pro-Ser-Ser-Gly-Ala-Pro-Pro-Pro-Ser-NH2

CAS: 2381089-83-2
Molecular mass: 4,731.33 g/mol
Purity target: ≥99%
Form: Lyophilized Powder

Vial 02

BPC-157 10mg

Sequence

Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val (GEPPPGKPADDAGLV)

CAS: 137525-51-0
Molecular mass: 1,419.5 g/mol
Purity target: ≥99%
Form: Lyophilized Powder

Form: 2 Separate Lyophilized Powders
Purity target: ≥99% per compound (3rd-Party HPLC Tested)
Origin: All Included Products: Synthesized, Formulated & Packaged in CA/AZ, USA
Storage: Store at -20°C (Freeze) or 2–8°C (Refrigerated) protected from light

What is the Retatrutide and BPC-157 Research Bundle?

This two-vial bundle pairs Retatrutide with BPC-157. Retatrutide is an investigational 39-amino-acid lipidated peptide designed to activate GIP, GLP-1, and glucagon receptors, while BPC-157 is a synthetic 15-amino-acid peptide used in models of vascular signaling, cell migration, and tissue-response pathways.

The compounds are supplied separately for independent or side-by-side study of two very different signaling profiles. The bundle does not imply a combined effect: Retatrutide remains investigational, and most BPC-157 evidence comes from cell and animal research.

How It Works

Retatrutide activates three receptor systems: GIPR, GLP-1R, and GCGR support study of nutrient- and energy-signaling activity.

BPC-157 engages cellular-response pathways: Preclinical work examines VEGFR2/Akt/eNOS, FAK-paxillin, nitric-oxide, and migration signaling.

Separate vials preserve experimental control: Study either material independently or compare distinct pathway responses without treating the bundle as one formulation.

Analytical data

One certificate per vial

Independent third-party HPLC assesses each compound against its ≥99% purity target, while mass spectrometry confirms identity. For each vial, the results are documented in one combined, batch-specific COA report.

Lot: RE-43145
Reported: 2026-04-23
Identity (LC-MS): Confirmed
Purity (HPLC-UV): 99.46%
Net content: 10.02 mg
Appearance: White lyophilized powder

Download COA

Lot: BP-79003
Reported: 2026-04-30
Identity (LC-MS): Confirmed
Purity (HPLC-UV): 99.58%
Net content: 10.01 mg
Appearance: White lyophilized powder

Download COA

Why Source from 321 Peptides?

Domestic accountability.

All included compounds are synthesized, manufactured, and finished in Certified GMP California and Arizona laboratory facilities—never sourced from overseas or Mexico. That means direct domestic supply-chain accountability from production through fulfillment.

Verification you can inspect.

Protected in transit.

Every included product is freeze-dried to help preserve stability during storage and shipping. Rapid domestic fulfillment reduces unnecessary time and handling.

Lot history 8 released lots

Every batch released under each vial in this bundle, with the figure reported for each. Vials are shipped from current stock.

Compound	Lot	Reported	Purity	Net content	COA
Retatrutide 10mg	R1399	2026-06-01	99.79%	11.74 mg	PDF
	RE-43145	2026-04-23	99.46%	10.02 mg	Pending
	RE-44299	2026-04-08	99.83%	10.04 mg	Pending
	RE-43722	2026-03-19	99.58%	10.03 mg	Pending
BPC-157 10mg	BP-79003	2026-04-30	99.58%	10.01 mg	Pending
	BP-80157	2026-04-23	99.49%	10.03 mg	Pending
	BP-35677	2026-04-23	99.46%	10.94 mg	PDF
	BP-79580	2026-02-25	99.83%	10.02 mg	Pending

Frequently Asked Questions

What comes in the Retatrutide and BPC-157 bundle?

The bundle includes Retatrutide 10mg; BPC-157 10mg. Each retail product arrives in its original lyophilized vial with batch-specific COA documentation.

How are Retatrutide and BPC-157 different?

Retatrutide is studied as a triple GIP, GLP-1, and glucagon receptor agonist. BPC-157 is studied mainly in preclinical vascular, cell-migration, and extracellular-matrix models.